NCT04699643View on ClinicalTrials.gov

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Advanced Solid Tumors

Interventions

DRUG

EVER4010001

Please refer to information in arm/group descriptions.

Trial Locations (1)

100071

RECRUITING

Department of Gastrointestinal Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing

Sponsors

Collaborators (1)

Medidata Solutions

All Listed Sponsors

collaborator

Medidata Solutions

INDUSTRY

lead

EverNov Medicines (Zhuhai Hengqin) Co., Ltd

INDUSTRY